Decisions 10th September 2013


Recent JFG Decisions

 

At the meeting on the 10th September 2013 the following decisions / changes to the formulary were agreed

 

New Drug Requests

Approved

Lixisenatide 

  • Approved for inclusion, TLS Green, first line.

Renavit

  • Approved for inclusion in the JF for the dietary management of water soluble vitamin deficiency in patients with chronic kidney disease in place of Dialyvit.  TLS blue for patients on renal dialysis.

     

Not approved

Linaclotide

  • Rejected as the clinical evidence did not support the inclusion into the formulary although the JFG acknowledged that this was a novel drug and there would be an emerging evidence base.

 

Deferred

Artiss

  • The JFG was unable to consider the application fully due to insufficient clinical evidence provided at this time. 

Teriparatide

  • The JFG was unable to consider the application fully due to insufficient clinical evidence provided.

 

Specialised Commissioning

  • No new statements

 

Shared Care Protocols

Methotrexate in Dermatology

  •  new SCP

Hydroxychloroquine in Dermatology

  • new SCP

 

Change in TLS

Prucalopride

  • change in TLS status from amber to blue on the advice of a specialist service

 

Tapentadol MR for chronic pain

  • change form TLS Red to TLS amber once SCP is finalised

 

Insulin Degludec  

  • request for change from TLS red to amber was not approved

 

Other Decisions

  • Natamycin - is commissioned by the CCG, UHB to submit a NDR

 

 

Last updated by: on 11-11-2013 14:47